Surgical management of sickle cell retinopathy: a systematic review of clinical outcomes and a single-arm meta-analysis of single-surgery anatomical success.

IF 2.4
Frontiers in ophthalmology Pub Date : 2026-07-23 eCollection Date: 2026-01-01 DOI:10.3389/fopht.2026.1842211
Maher Nassor, Ahmed Bakr, Usman Muhammad, Marwan Tahoun
{"title":"Surgical management of sickle cell retinopathy: a systematic review of clinical outcomes and a single-arm meta-analysis of single-surgery anatomical success.","authors":"Maher Nassor, Ahmed Bakr, Usman Muhammad, Marwan Tahoun","doi":"10.3389/fopht.2026.1842211","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Sickle cell retinopathy is a consequence of sickle cell disease that results from vascular complications. Sickle cell disease is predominantly prevalent in Africa, evidenced by 20% to 30% of the population in Gabon, Cameroon, and Ghana being affected by it. This systematic review aims to evaluate the surgical outcomes of patients with sickle cell retinopathy to inform evidence-based management of late stages of sickle cell retinopathy.</p><p><strong>Methods: </strong>This systematic review was conducted in accordance with the PRISMA 2020 guidelines. A Literature search was conducted on PubMed, Embase (Ovid), and Cochrane (CENTRAL) on 05/08/2025. Inclusion criteria included studies with patients with sickle cell retinopathy who underwent surgery and reported anatomical and/or visual outcomes. A random effects single-arm meta-analysis was carried out in the anatomical success group using JASP software, and the risk of bias was evaluated using JBI and RoB2 tools.</p><p><strong>Results: </strong>7 studies, comprising 408 eyes, were included. Overall, the evidence showed that surgical treatment in patients with sickle cell retinopathy results in improved final visual acuity and high single-surgery anatomical success (SSAS, between 60% to 83%). The pooled SSAS data, based on logit-transformed proportions, yielded an effect of 0.83 (95% CI: 0.24-1.42), corresponding to a pooled SSAS of approximately 70% (95% CI: 56-80%), with low, non-significant heterogeneity among the included studies (Q (4) = 5.61, p = 0.230; I² = 29.73% [0.00, 92.46]). Leave-one-out sensitivity analysis confirmed that the estimate was robust, with the pooled SSAS ranging from approximately 66% to 74% across iterations.</p><p><strong>Discussion: </strong>Studies have reported a considerable gain in final visual acuity and anatomical success in patients undergoing surgery for sickle cell retinopathy. The small number of studies and small sample sizes increase heterogeneity. Therefore, although the results indicate favourable surgical outcomes, clinicians must weigh up the benefits of surgery against possible complications. In conclusion, more studies are warranted to guide evidence-based medicine.</p><p><strong>Systematic review registration: </strong>https://www.crd.york.ac.uk/PROSPERO/view/CRD420251165357, identifier CRD420251165357.</p>","PeriodicalId":73096,"journal":{"name":"Frontiers in ophthalmology","volume":"6 ","pages":"1842211"},"PeriodicalIF":2.4000,"publicationDate":"2026-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13441773/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in ophthalmology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3389/fopht.2026.1842211","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Sickle cell retinopathy is a consequence of sickle cell disease that results from vascular complications. Sickle cell disease is predominantly prevalent in Africa, evidenced by 20% to 30% of the population in Gabon, Cameroon, and Ghana being affected by it. This systematic review aims to evaluate the surgical outcomes of patients with sickle cell retinopathy to inform evidence-based management of late stages of sickle cell retinopathy.

Methods: This systematic review was conducted in accordance with the PRISMA 2020 guidelines. A Literature search was conducted on PubMed, Embase (Ovid), and Cochrane (CENTRAL) on 05/08/2025. Inclusion criteria included studies with patients with sickle cell retinopathy who underwent surgery and reported anatomical and/or visual outcomes. A random effects single-arm meta-analysis was carried out in the anatomical success group using JASP software, and the risk of bias was evaluated using JBI and RoB2 tools.

Results: 7 studies, comprising 408 eyes, were included. Overall, the evidence showed that surgical treatment in patients with sickle cell retinopathy results in improved final visual acuity and high single-surgery anatomical success (SSAS, between 60% to 83%). The pooled SSAS data, based on logit-transformed proportions, yielded an effect of 0.83 (95% CI: 0.24-1.42), corresponding to a pooled SSAS of approximately 70% (95% CI: 56-80%), with low, non-significant heterogeneity among the included studies (Q (4) = 5.61, p = 0.230; I² = 29.73% [0.00, 92.46]). Leave-one-out sensitivity analysis confirmed that the estimate was robust, with the pooled SSAS ranging from approximately 66% to 74% across iterations.

Discussion: Studies have reported a considerable gain in final visual acuity and anatomical success in patients undergoing surgery for sickle cell retinopathy. The small number of studies and small sample sizes increase heterogeneity. Therefore, although the results indicate favourable surgical outcomes, clinicians must weigh up the benefits of surgery against possible complications. In conclusion, more studies are warranted to guide evidence-based medicine.

Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD420251165357, identifier CRD420251165357.

镰状细胞视网膜病变的手术治疗:临床结果的系统回顾和单次手术解剖成功的单臂荟萃分析。
简介:镰状细胞视网膜病变是镰状细胞病引起的血管并发症的结果。镰状细胞病主要在非洲流行,加蓬、喀麦隆和加纳有20%至30%的人口受其影响。本系统综述旨在评估镰状细胞视网膜病变患者的手术结果,为晚期镰状细胞视网膜病变的循证管理提供依据。方法:本系统评价按照PRISMA 2020指南进行。于2025年5月8日在PubMed、Embase (Ovid)和Cochrane (CENTRAL)上进行文献检索。纳入标准包括镰状细胞视网膜病变患者接受手术并报告解剖和/或视力结果的研究。采用JASP软件对解剖成功组进行随机效应单臂meta分析,并采用JBI和RoB2工具评估偏倚风险。结果:纳入7项研究,共408只眼。总的来说,有证据表明,镰状细胞视网膜病变患者的手术治疗可改善最终视力和较高的单次手术解剖成功率(SSAS在60%至83%之间)。基于对数变换比例的合并SSAS数据产生了0.83 (95% CI: 0.24-1.42)的效应,对应于合并SSAS约为70% (95% CI: 56-80%),所纳入研究之间具有低的非显著异质性(Q (4) = 5.61, p = 0.230;I²= 29.73%[0.00,92.46])。留一敏感性分析确认了评估是稳健的,在迭代过程中,混合的SSAS从大约66%到74%不等。讨论:研究报告了镰状细胞视网膜病变手术患者的最终视力和解剖学上的成功。研究数量少和样本量小增加了异质性。因此,尽管结果显示良好的手术结果,临床医生必须权衡手术的好处和可能的并发症。总之,有必要进行更多的研究来指导循证医学。系统综述注册:https://www.crd.york.ac.uk/PROSPERO/view/CRD420251165357,标识符CRD420251165357。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
0.50
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书